We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

48 hedge funds and large institutions have $106M invested in Inhibikase Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

4.1% more ownership

Funds ownership: 69.23% → 73.33% (+4.1%)

2% more funds holding

Funds holding: 47 → 48 (+1)

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less capital invested

Capital invested by funds: $113M → $106M (-$6.4M)

Holders
48
Holders Change
+1
Holders Change %
+2.13%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
24
Increased
11
Reduced
6
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.51M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.45M
3
Blackstone Inc
Blackstone Inc
New York
+$1.11M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$736K
5
State Street
State Street
Massachusetts
+$697K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2M
2
PA
Perceptive Advisors
New York
-$965K
3
Goldman Sachs
Goldman Sachs
New York
-$364K
4
SCM
Stonepine Capital Management
Oregon
-$355K
5
Marshall Wace
Marshall Wace
United Kingdom
-$340K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$74.7K +$74.7K +38,159 +22,850%
Mirae Asset Global ETFs Holdings
27
Mirae Asset Global ETFs Holdings
Hong Kong
$64.4K +$64.7K +33,023 New
IIM
28
INTECH Investment Management
Florida
$61.2K +$61.5K +31,406 New
LP
29
LMR Partners
United Kingdom
$60.6K – – –
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$60K +$59.9K +30,606 New
Invesco
31
Invesco
Georgia
$59.9K +$60.1K +30,712 New
JP Morgan Chase
32
JP Morgan Chase
New York
$55.7K +$56K +28,579 New
Citigroup
33
Citigroup
New York
$39.8K -$10.5K -5,372 -21%
Bank of America
34
Bank of America
North Carolina
$37.5K -$50.5K -25,810 -57%
VOYA Investment Management
35
VOYA Investment Management
Georgia
$36.6K +$36.7K +18,755 New
PFSRSONJ
36
Police & Firemen's Retirement System of New Jersey
New Jersey
$34.4K +$34.5K +17,638 New
CC
37
Caxton Corporation
New Jersey
$32K – – –
ProShare Advisors
38
ProShare Advisors
Maryland
$24.2K +$24.3K +12,401 New
FPAS
39
Focus Partners Advisor Solutions
Missouri
$20.9K +$21K +10,708 New
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$17.9K +$18K +9,182 New
AIP
41
Ameritas Investment Partners
Nebraska
$12K +$12.1K +6,174 New
Legal & General Group
42
Legal & General Group
United Kingdom
$10.7K +$10.8K +5,504 New
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$10K +$8.98K +4,587 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$7.36K +$7.39K +3,773 New
AB
45
Amalgamated Bank
New York
$4K +$4.04K +2,065 New
SCM
46
Sterling Capital Management
North Carolina
$2.94K +$2.95K +1,505 New
Raymond James Financial
47
Raymond James Financial
Florida
$1.95K +$1.96K +1,000 New
TRCT
48
Tower Research Capital (TRC)
New York
$195 +$196 +100 New
Millennium Management
49
Millennium Management
New York
– -$2M -913,502 Closed
Goldman Sachs
50
Goldman Sachs
New York
– -$364K -166,025 Closed
1
2
3

IKT Hedge Fund Activity: Q2 2025 in Review

48 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2025, worth a combined $106M — down 5.7% from $113M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new IKT positions and 23 closed out — a net gain of 1 holder — while 11 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $4.51M. The largest seller was Millennium Management, exiting entirely with an estimated $2M sold.

  • 48 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2025, up from 47 in Q1 2025.
  • Funds reported $106M of Inhibikase Therapeutics stock for Q2 2025, down 5.7% quarter-over-quarter.
  • 24 funds opened new Inhibikase Therapeutics positions in Q2 2025 and 23 closed out, a net change of +1 holder.
  • The largest Inhibikase Therapeutics buyer in Q2 2025 was BlackRock, an estimated $4.51M added.
  • The largest Inhibikase Therapeutics seller in Q2 2025 was Millennium Management, an estimated $2M sold.

Based on aggregated 13F filings for Q2 2025.